Navigating FDA Diversity Action Plans: A 2026 Compliance Guide for Sponsors

As of November 2026, an FDA Diversity Action Plan is a statutory requirement for applicable clinical trials, not a recommendation. FDORA, enacted in December 2022, obligates sponsors of certain drug and biological product trials to submit enrollment goals and outreach strategies for underrepresented populations before the study starts. If your pivotal trial lacks a credible DAP, FDA can treat that as a review issue—so treat it as a go/no-go filter, not paperwork.

Key takeaways

• DAPs are required by statute under FDORA for applicable trials, primarily Phase 3 and other pivotal studies supporting an NDA or BLA.
• The plan must state enrollment goals, the rationale for those goals, and concrete strategies to reach them.
• FDA evaluates the DAP as part of the overall application; a weak plan can slow review or narrow labeling.
• Goals should match the disease’s real-world epidemiology, not arbitrary national averages.
• Budget for DAP execution during CRO selection and site contracting, not after the first patient is enrolled.

What is the FDA Diversity Action Plan, and who does it affect in 2026?

A Diversity Action Plan is a sponsor’s written commitment to enroll a patient population that reflects who will actually use the drug. Under FDORA, it applies to applicable clinical trials—generally Phase 3 and other pivotal trials for drugs and biologics that will support a marketing application. Early-phase studies and certain exempt trials are excluded, but if you are heading toward registration, you need one.

The statute was enacted in December 2022, and by 2026 it is fully in force for applicable trials. Regulatory trackers and industry blogs maintain reference pages on DAP status; I use CASRAI’s FDA Diversity Action Plan resource and Ditto’s clinical trial diversity statistics as starting points, then verify every number against the specific disease and trial design.

Who is responsible? The sponsor. That means if you are a biotech founder, this is on you, not something you can delegate entirely to a CRO. The plan must be submitted to FDA, and reviewers will check whether the enrollment goals are plausible given the sites and protocol you have proposed.

What are the key requirements for Diversity Action Plans under FDORA?

The FDA expects three core elements: enrollment goals for underrepresented racial and ethnic groups, a rationale tied to disease prevalence, and specific strategies to meet those goals. It is not enough to say “we will recruit broadly.” The plan must show FDA that your goals are plausible and that your operational plan can deliver them.

One detail that surprises first-time sponsors: the DAP is not a quota system. FDA does not require you to enroll a fixed percentage of any group. It requires you to justify your goals and show a credible path to them. If your disease predominantly affects older adults, for example, your age goals should reflect that, and your rationale should say so.

How do I develop and implement an effective Diversity Action Plan?

I would always build the DAP before site selection, not after. The plan should drive which sites you contract, not the other way around.

Start with the epidemiology of the disease in the populations you intend to treat. Then map those demographics to potential sites. A site in a homogeneous catchment area cannot meet a goal it was never positioned to hit. If your target population includes Spanish-speaking patients, your consent forms, screening scripts, and study visits need to work in Spanish before the first site is activated.

Operational supports matter as much as scientific ones. Offer transportation stipends, flexible visit windows, and decentralized options where appropriate. Decentralized Clinical Trials: Navigating the Regulatory and Operational Realities in 2026 covers how remote visits can reduce the burden that keeps underrepresented patients out of trials.

When you evaluate CROs, ask how they handle diversity tracking in their site feasibility assessments. Optimizing Clinical Trial Site Selection: A Data-Driven Framework for 2026 is the framework I use to avoid signing up sites that look good on paper but cannot reach the patients in your DAP.

How should I measure and report diversity in a clinical trial?

There is no universal diversity quota. The defensible benchmark is the prevalence of the disease in the populations you intend to treat, then adjust for access and referral patterns. Track screening, enrollment, and retention by demographic group, and report actuals against goals at defined intervals.

Metrics I track:

• Screening failure rate by race, ethnicity, and sex
• Enrollment actuals versus DAP goals, by quarter
• Retention and dropout rates across demographic subgroups
• Language and geographic barriers logged at screen failure

If a subgroup is screening out at twice the rate of others, that is a protocol problem, not a patient problem. Risk-Based Monitoring in 2026: Beyond Compliance to Predictive Quality describes how to catch these signals early enough to amend the protocol before the database locks.

How does diversity affect clinical trial success and regulatory decisions?

Diversity changes the label. If a pivotal trial enrolls a narrow population, FDA may limit the indication or require post-marketing studies, which changes the commercial case and your go/no-go math. I have seen teams discover too late that their safety database missed signals present in underrepresented groups, forcing expensive supplemental studies after approval.

This is especially relevant for accelerated approval. Navigating the FDA's Evolving Accelerated Approval Pathway: A 2026 Guide for Biotech and Pharma explains how FDA weighs confirmatory evidence; a homogeneous trial weakens that evidence package.

From a feasibility standpoint, I treat DAP credibility as a gating question. If the sites you have lined up cannot plausibly reach the enrollment goals in your plan, the plan is fiction—and FDA reviewers will notice.

What challenges come with achieving clinical trial diversity, and how do I fix them?

The biggest obstacles are usually protocol design, not patient refusal. Narrow eligibility criteria, single-language materials, and inflexible visit schedules systematically exclude the populations the DAP is meant to include.

Common challenges and how I address them:

• Restrictive eligibility criteria: Excluding common comorbidities that disproportionately affect underrepresented groups shrinks your eligible pool. Broadening criteria where scientifically sound is a faster fix than more advertising.
• Single-language materials: If consent and diaries are English-only, you are self-selecting out non-English speakers. Translate early and back-translate to verify.
• Rigid visit schedules: Inflexible windows exclude hourly workers and caregivers. Decentralized visits or local lab draws can close the gap.
• Mistrust and awareness: Community partnerships take longer than a recruitment vendor can deliver in six weeks. Start them during protocol design.

Patient retention is where many DAPs fail after enrollment. Clinical Trial Patient Retention Strategies: A 2026 Guide to Minimizing Dropouts and Maximizing Data Quality covers the operational side of keeping enrolled patients through follow-up.

Before you submit your IND or finalize your CRO contract, run the DAP through a feasibility lens. We treat DAP readiness as one of six pillars in our assessment because a recruitment plan that looks good on paper often fails at site level. See how Clinical Trial OS structures feasibility and go/no-go decisions.

FAQ

When must a Diversity Action Plan be submitted to the FDA?

For applicable trials, the DAP is submitted to FDA as part of the development program, generally before the pivotal trial begins or with the marketing application, depending on the submission pathway. Do not wait until the NDA or BLA is ready to file.

Does every clinical trial need a DAP?

No. The requirement applies to applicable clinical trials, primarily Phase 3 and other pivotal trials for drugs and biologics that support a marketing application. Early-phase trials and certain exempt studies are not covered, though sponsors often volunteer diversity goals anyway.

What happens if enrollment goals are missed?

FDA reviews whether the sponsor made a good-faith effort and whether the shortfall affects the ability to assess safety and effectiveness across populations. A missed goal is not an automatic rejection, but it can trigger post-marketing requirements or limit labeling claims.

How is a DAP different from FDA inclusion guidelines?

Inclusion guidance describes who should be considered for clinical research generally. A DAP is a trial-specific, statutory commitment with enrollment goals, rationale, and strategies tied to a particular application.

Do accelerated approval programs still require a DAP?

Yes. If the trial is an applicable clinical trial supporting a drug or biological product application, the DAP requirement applies regardless of whether you are pursuing accelerated, traditional, or another approval pathway.